Protective effects of carvedilol in the myocardium

American Journal of Cardiology

Volumn 80, Issue 11 A, 1997, Pages

  Feuerstein, Giora Z ^a   Bril, Antoine ^a   Ruffolo Jr , Robert R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; NORADRENALIN;

BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG EFFECT; HEART MUSCLE; HEART PROTECTION; HUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; VASODILATATION;

EID: 0030681374     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00847-3     Document Type: Conference Paper

References (29)

1. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J. 17:(suppl B):1996;24-29.
2. Kramer JH, Weglicki WB. A hydroxylated analog of the β-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Free Radic Biol Med. 21:1996;813-825.
3. 3/ADP on reperfusion arrhythmias of rat hearts and electrical activity of canine Purkinje fibres. Cardiovasc Res. 24:1990;669-675.
4. Bril A, Tomasi V, Laville MP. Antiarrhythmic effect of carvedilol in rat isolated heart subjected to regional ischemia and reperfusion. Pharmacol Commun. 5:1995;291-300.
5. Ma XL, Yue TL, Lopez BL, Barone FC, Christopher TA, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new beta adrenoceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther. 277:1996;128-136.
6. Feuerstein GZ, Yue TL. Apoptosis and the heart. Basic and Applied Myology. 6:1996;221-225.
7. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 94:1994;1621-1628.
8. Feuerstein GZ, Hamburger SA, Smith EF, Bril A, Ruffolo RR Jr. Myocardial protection with carvedilol. J Cardiovasc Pharmacol. 19:1992;S138-S141.
9. Hamburger SA, Barone FC, Feuerstein GZ, Ruffolo RR Jr. Carvedilol (kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology. 43:1991;113-120.
10. Bril A, Slivjak MJ, Dimartino MJ, Feuerstein GZ, Linee P, Poyser RH, Ruffolo RR Jr, Smith EF III. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs comparison with propranolol . Cardiovasc Res. 26:1992;518-525.
11. Brunvand H, Kvitting PM, Rynning SE, Berge RK, Grong K. Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms. J Cardiovasc Pharmacol. 28:1996;409-417.
12. Brunvand H, Froyland L, Hexeberg E, Rynning SE, Berge RK, Grong K. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. Eur J Pharmacol. 314:1996;99-107.
13. Feuerstein GZ, Yue TL, Cheng HY, Ruffolo RR Jr. Myocardial protection by the novel vasodilating beta-blocker, carvedilol potential relevance of antioxidant activity . J Hypertens. 11:(suppl 4):1993;S41-S48.
14. James TN. Normal and abnormal consequences of apoptosis in the human heart from postnatal morphogenesis to paroxysmal arrhythmias . Circulation. 90:1994;556-573.
15. Yue TL, Wang X, Gu JL, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a novel vasodilating beta-adrenoceptor antagonist, prevents low-density lipoprotein (LDL)-enhanced leukocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol. 294:1995;585-591.
16. Yue TL, Wang X, Gu JL, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new vasodilating β-adrenoceptor blocker, inhibits oxidation of low density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther. 273:1995;1442-1449.
17. Yue TL, McKenna PJ, Gu JL, Cheng HY, Ruffolo RE Jr, Feuerstein GZ. Carvedilol, a new vasodilating β-adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc Res. 28:1994;400-406.
18. Yue TL, McKenna PJ, Gu JL, Cheng HY, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new hypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension. 22:1993;922-928.
19. Yue TL, Liu T, Feuerstein GZ. Carvedilol, a new beta adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun. 1:1992;27-35.
20. Yue TL, McKenna PJ, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new β-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol. 214:1992;277-280.
21. Cheng H-Y, Randall CS, Holl WW, Constantinides PP, Yue TL, Feuerstein GZ. Carvedilol-liposome interaction evidence for strong association with the hydrophobic region of the lipid bilayers . Biochem Biophys Acta. 128:1996;20-28.
22. Podrid PJ, Fogel RI, Tordjman-Fuchs T. Arrhythmia in patients with cardiomyopathy and congestive heart failure. In: Hosenpund JD, Greenberg BA, eds. Congestive Heart Failure. New York: Springer Verlag, 1994:645-686.
23. Bril A, Forest MC, Gout B. Ischemia and reperfusion-induced arrhythmias in rabbits with chronic heart failure. Am J Physiol. 261:1991;H301-H307.
24. Rochette L, Ribuot C, Bélichard P, Bril A, Devissaguet M. Protective effect of angiotensin converting enzyme inhibitors (ACEI) captopril and perindopril on vulnerability to ventricular fibrillation during myocardial ischaemia and reperfusion in rats. Clin Exp Hypertens. 9:1987;365-368.
25. Arleth AJ, Storer B, Romanic AM, Ohlstein EH. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. (Abstr.). Circulation. 94:(suppl):1996;I-401.
26. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Ingersoll H. Multicenter oral carvedilol heart failure assessment (MOCHA) a six-month dose-response evaluation in class II-IV patients. (Abstr.) . Circulation. 92:1995;I-142.
27. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
28. Bing OHL. Hypothesis apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload . J Mol Cell Cardiol. 26:1994;943-948.
29. Teiger E, Than VD, Richard L, Wisnewsky C, Tea BS, Gaboury L, Tremblay J, Schwartz K, Hamet P. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest. 97:1996;2891-2897.